Reason for request
Renewal of of the proprietary products BONVIVA 150 mg/1 month tablet (box of 1 and 3) and BONVIVA 3 mg/3 months (box of 1) on the list of medicines by National Health Insurance the renewal of of BONDRONAT solution for injection and re-assessment of the actual benefit of the proprietary product BONVIVA 3 mg/3 months solution for injection, box of 4, in accordance with article R. 163-21 of the Social Security Code.
Clinical Benefit
| Insufficient |
The actual benefit of these proprietary products in comparison with the treatments that are already available is not sufficient to justify reimbursement by National Health Insurance. |
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
cuUk4vryTx679ZtZ
